Q2 Korean Biotech Roundup: Partners Return Multiple Assets
U-Turns For OliX, Artiva, Voronoi
The second quarter in South Korea was marked by the return of several assets by licensing partners, including Thea Open Innovation, which gave back rights to two ophthalmic programs in-licensed from OliX. Merck & Co. also cancelled a co-research deal with Artiva Biotherapeutics.
